What is the difference between small cell and non-small cell lung cancer?
Small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the two primary histological and biological categories of lung malignancies, which differ fundamentally in their biological behaviour, incidence rates, and therapeutic approaches. Non-small cell lung cancer accounts for approximately 85% of all lung cancer cases and is subdivided mainly into adenocarcinoma, squamous cell carcinoma, and large cell carcinoma, whereas small cell lung cancer is a less common type exhibiting neuroendocrine characteristics. NSCLC may have a slower growth rate, surgical resection represents an essential curative treatment modality in its early stages, and in its advanced forms, targeted therapies based on molecular genetic alterations (such as EGFR, ALK, KRAS, ROS1) and immunotherapies constitute the cornerstones of management. In contrast, SCLC is biologically markedly aggressive, possesses an extremely rapid doubling time, and in the vast majority of patients at the time of diagnosis, early micrometastases or widespread distant metastases are already present, which is why primary surgical management is very rarely indicated. The standard management of SCLC is systemic in nature: a combination of chemotherapy and immunotherapy, alongside radiotherapy, forms its backbone; this may initially demonstrate a good tumour response, but rapid recurrence and treatment resistance frequently develop. Furthermore, differences are also observed in the therapeutic toxicity profiles of the two histological types; for instance, in the context of antibody-drug conjugate (ADC) administration, the rate of overall pulmonary adverse events is higher in small cell lung cancer, whereas pneumonitis is more common in NSCLC.
During systemic treatments, including the administration of antibody-drug conjugates (ADCs), it has been demonstrated that the distribution of pulmonary adverse events differs between the two entities: in small cell lung cancer, any-grade pulmonary adverse events are significantly more frequent (52.1% vs. 22.5%), whereas in non-small cell lung cancer, the incidence of pneumonitis is higher (12.1% vs. 2.8%). Furthermore, during the treatment of EGFR-mutant non-small cell lung cancers with tyrosine kinase inhibitors (TKIs), transformation into small cell lung cancer (T-SCLC) may also occur as an acquired resistance mechanism, which entails an altered immune microenvironment and the necessity of therapeutic modification.
References
- Pulmonary Toxicities of Antibody-Drug Conjugates in Small Cell and Non-Small Cell Lung Cancer: A Systematic Review and Meta-analysis. PMID 42674256
- Transcriptomic profiling of lineage transformation and actionable therapy opportunities in EGFR-mutant non-small cell lung cancer evolving to small cell lung cancer. PMID 42681635
- Prognostic and therapeutic importance of TROP-2 and MUC-1 in non-small cell lung cancer: A systematic review and meta-analysis. PMID 42614905